Irene M. Ghobrial spends much of her time researching Internal medicine, Multiple myeloma, Bone marrow, Bortezomib and Cancer research. Irene M. Ghobrial combines subjects such as Gastroenterology, Surgery and Oncology with her study of Internal medicine. Her Multiple myeloma research also works with subjects such as
Her Bone marrow research is multidisciplinary, relying on both Osteoclast, Stromal cell, Haematopoiesis and Cell biology. Her Bortezomib research incorporates themes from Proteasome inhibitor, Lenalidomide, Dexamethasone, Pharmacology and PLGA. Her Cancer research study integrates concerns from other disciplines, such as Apoptosis, microRNA, Stem cell, CD19 and Gene silencing.
Her scientific interests lie mostly in Internal medicine, Multiple myeloma, Cancer research, Bone marrow and Bortezomib. Her Internal medicine research includes elements of Gastroenterology, Surgery and Oncology. The various areas that Irene M. Ghobrial examines in her Multiple myeloma study include Monoclonal gammopathy of undetermined significance, Clinical trial, Disease and Transplantation.
Her Cancer research research focuses on Cell growth and how it relates to Cell cycle. The study incorporates disciplines such as Tumor microenvironment, Cell culture and In vivo in addition to Bone marrow. Her Bortezomib research is multidisciplinary, incorporating elements of Proteasome inhibitor, Phases of clinical research, Neutropenia, Dexamethasone and Pharmacology.
Irene M. Ghobrial mainly investigates Multiple myeloma, Cancer research, Internal medicine, Oncology and Bone marrow. Her Multiple myeloma research includes themes of Disease progression, Computational biology and Monoclonal gammopathy of undetermined significance. Her research in the fields of Tumor microenvironment overlaps with other disciplines such as Extramural.
Her research in Internal medicine focuses on subjects like Gastroenterology, which are connected to Waldenstrom macroglobulinemia and Asymptomatic. Her Oncology study deals with Cancer intersecting with Haematopoiesis. Irene M. Ghobrial has researched Bone marrow in several fields, including Tumor progression and In vitro.
Her primary areas of study are Multiple myeloma, Cancer research, Internal medicine, Bone marrow and Oncology. Her studies in Multiple myeloma integrate themes in fields like Disease progression, Haematopoiesis, Cancer, Tolerability and Neutropenia. In general Cancer research, her work in Tumor microenvironment is often linked to Extramural linking many areas of study.
As a part of the same scientific family, she mostly works in the field of Internal medicine, focusing on Gastroenterology and, on occasion, Waldenstrom macroglobulinemia, Asymptomatic and Macroglobulinemia. Her research in Bone marrow intersects with topics in Monoclonal gammopathy of undetermined significance, In vitro, Disease, Mesenchymal stem cell and Bone remodeling. Her studies deal with areas such as Previously treated, Clinical trial and Stem cell as well as Oncology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Biological properties of extracellular vesicles and their physiological functions
María Yáñez-Mó;Pia R.-M. Siljander;Zoraida Andreu;Apolonija Bedina Zavec.
Journal of extracellular vesicles (2015)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore;Ghayas C. Issa;Madeleine E. Lemieux;Peter B. Rahl.
Targeting apoptosis pathways in cancer therapy.
Irene M. Ghobrial;Thomas E. Witzig;Alex A. Adjei.
CA: A Cancer Journal for Clinicians (2005)
Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study.
Long H. Nguyen;David A. Drew;Mark S. Graham;Amit D. Joshi.
The Lancet. Public health (2020)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Paul G. Richardson;Edie Weller;Sagar Lonial;Andrzej J. Jakubowiak.
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
Steven P. Treon;Christina K. Tripsas;Kirsten Meid;Diane Warren.
The New England Journal of Medicine (2015)
BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression
Aldo M. Roccaro;Antonio Sacco;Patricia Maiso;Abdel Kareem Azab.
Journal of Clinical Investigation (2013)
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
Thomas E. Witzig;Susan M. Geyer;Irene Ghobrial;David J. Inwards.
Journal of Clinical Oncology (2005)
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
Yazan Alsayed;Hai Ngo;Judith Runnels;Xavier Leleu.
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
Abdel Kareem Azab;Judith M. Runnels;Costas Pitsillides;Anne-Sophie Moreau.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: